Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

Mary J. Thomson; Marina Serper; Vandana Khungar; L. Michael Weiss; Huy Trinh; Roberto Firpi-Morell; Michael Roden; Rohit Loomba; A. Sidney Barritt; Derek Gazis; Andrea R. Mospan; Michael W. Fried; K. Rajender Reddy; Anna S. Lok

doi:10.1016/j.cgh.2021.03.031

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

Mary J. Thomson, Marina Serper, Vandana Khungar, L. Michael Weiss, Huy Trinh, Roberto Firpi-Morell, Michael Roden, Rohit Loomba, A. Sidney Barritt, Derek Gazis, Andrea R. Mospan, Michael W. Fried, K. Rajender Reddy, Anna S. Lok

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events. 1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis, 2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma. 3 , 4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. 5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.

Original language	English (US)
Pages (from-to)	458-460.e4
Journal	Clinical Gastroenterology and Hepatology
Volume	20
Issue number	2
Early online date	Mar 26 2021
DOIs	https://doi.org/10.1016/j.cgh.2021.03.031
State	Published - Feb 2022

Bibliographical note

Funding Information:
Funding Marina Serper receives funding from the National Institutes of Health (award 1K23DK1158907-03 ). Mary Thomson receives funding from the American Association for the Study of Liver Diseases Advanced/Transplant Hepatology Award. TARGET-NASH is a collaboration among academic and community investigators and the pharmaceutical industry. Target RWE is the sponsor of the TARGET-NASH study. We thank the study staff, nurses, health care providers, and participants at each study center for their contributions to this work.

Funding Information:
Conflicts of interest These authors disclose the following: Marina Serper has received consulting fees from Gilead. Huy Trinh has served as a speaker and advisor for and owns stock in Gilead; and has received grant support from Gilead and Intercept. Michael Roden has served on the scientific advisory boards of Allergan, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Inventiva, Intercept Pharma, Novartis, Novo Nordisk, Servier Laboratories, Target Pharma Solutions, and Terra Firma; and has received investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone, and Sanofi. Derek Gazis and Andrea R. Mospan are employees of Target RWE. Michael W. Fried is is Chief Medical Officer of Target RWE and is a stockholder in the company. K. Rajender Reddy has received research grants (paid to the University of Pennsylvania) for the HCV-TARGET, TARGET-HCC, and TARGET-NASH studies. Anna S. Lok has received research grants (to University of Michigan) from and served as advisor to Target RWE; and has served on the Data and Safety Monitoring Board for Novo Nordisk. The remaining authors disclose no conflicts.

Funding Information:
Funding Marina Serper receives funding from the National Institutes of Health (award 1K23DK1158907-03). Mary Thomson receives funding from the American Association for the Study of Liver Diseases Advanced/Transplant Hepatology Award. TARGET-NASH is a collaboration among academic and community investigators and the pharmaceutical industry. Target RWE is the sponsor of the TARGET-NASH study. We thank the study staff, nurses, health care providers, and participants at each study center for their contributions to this work. Conflicts of interest These authors disclose the following: Marina Serper has received consulting fees from Gilead. Huy Trinh has served as a speaker and advisor for and owns stock in Gilead; and has received grant support from Gilead and Intercept. Michael Roden has served on the scientific advisory boards of Allergan, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Inventiva, Intercept Pharma, Novartis, Novo Nordisk, Servier Laboratories, Target Pharma Solutions, and Terra Firma; and has received investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone, and Sanofi. Derek Gazis and Andrea R. Mospan are employees of Target RWE. Michael W. Fried is is Chief Medical Officer of Target RWE and is a stockholder in the company. K. Rajender Reddy has received research grants (paid to the University of Pennsylvania) for the HCV-TARGET, TARGET-HCC, and TARGET-NASH studies. Anna S. Lok has received research grants (to University of Michigan) from and served as advisor to Target RWE; and has served on the Data and Safety Monitoring Board for Novo Nordisk. The remaining authors disclose no conflicts.

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.cgh.2021.03.031

Find It

Find It at U of M Libraries

Cite this

Thomson, M. J., Serper, M., Khungar, V., Weiss, L. M., Trinh, H., Firpi-Morell, R., Roden, M., Loomba, R., Barritt, A. S., Gazis, D., Mospan, A. R., Fried, M. W., Reddy, K. R., & Lok, A. S. (2022). Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clinical Gastroenterology and Hepatology, 20(2), 458-460.e4. https://doi.org/10.1016/j.cgh.2021.03.031

Thomson, MJ, Serper, M, Khungar, V, Weiss, LM, Trinh, H, Firpi-Morell, R, Roden, M, Loomba, R, Barritt, AS, Gazis, D, Mospan, AR, Fried, MW, Reddy, KR & Lok, AS 2022, 'Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study', Clinical Gastroenterology and Hepatology, vol. 20, no. 2, pp. 458-460.e4. https://doi.org/10.1016/j.cgh.2021.03.031

@article{bc78d0ae948a402186c8b0e675ac91fe,

title = "Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study",

abstract = "Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events. 1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis, 2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma. 3 , 4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. 5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort. ",

author = "Thomson, {Mary J.} and Marina Serper and Vandana Khungar and Weiss, {L. Michael} and Huy Trinh and Roberto Firpi-Morell and Michael Roden and Rohit Loomba and Barritt, {A. Sidney} and Derek Gazis and Mospan, {Andrea R.} and Fried, {Michael W.} and Reddy, {K. Rajender} and Lok, {Anna S.}",

note = "Funding Information: Funding Marina Serper receives funding from the National Institutes of Health (award 1K23DK1158907-03 ). Mary Thomson receives funding from the American Association for the Study of Liver Diseases Advanced/Transplant Hepatology Award. TARGET-NASH is a collaboration among academic and community investigators and the pharmaceutical industry. Target RWE is the sponsor of the TARGET-NASH study. We thank the study staff, nurses, health care providers, and participants at each study center for their contributions to this work. Funding Information: Conflicts of interest These authors disclose the following: Marina Serper has received consulting fees from Gilead. Huy Trinh has served as a speaker and advisor for and owns stock in Gilead; and has received grant support from Gilead and Intercept. Michael Roden has served on the scientific advisory boards of Allergan, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Inventiva, Intercept Pharma, Novartis, Novo Nordisk, Servier Laboratories, Target Pharma Solutions, and Terra Firma; and has received investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone, and Sanofi. Derek Gazis and Andrea R. Mospan are employees of Target RWE. Michael W. Fried is is Chief Medical Officer of Target RWE and is a stockholder in the company. K. Rajender Reddy has received research grants (paid to the University of Pennsylvania) for the HCV-TARGET, TARGET-HCC, and TARGET-NASH studies. Anna S. Lok has received research grants (to University of Michigan) from and served as advisor to Target RWE; and has served on the Data and Safety Monitoring Board for Novo Nordisk. The remaining authors disclose no conflicts. Funding Information: Funding Marina Serper receives funding from the National Institutes of Health (award 1K23DK1158907-03). Mary Thomson receives funding from the American Association for the Study of Liver Diseases Advanced/Transplant Hepatology Award. TARGET-NASH is a collaboration among academic and community investigators and the pharmaceutical industry. Target RWE is the sponsor of the TARGET-NASH study. We thank the study staff, nurses, health care providers, and participants at each study center for their contributions to this work. Conflicts of interest These authors disclose the following: Marina Serper has received consulting fees from Gilead. Huy Trinh has served as a speaker and advisor for and owns stock in Gilead; and has received grant support from Gilead and Intercept. Michael Roden has served on the scientific advisory boards of Allergan, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Inventiva, Intercept Pharma, Novartis, Novo Nordisk, Servier Laboratories, Target Pharma Solutions, and Terra Firma; and has received investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone, and Sanofi. Derek Gazis and Andrea R. Mospan are employees of Target RWE. Michael W. Fried is is Chief Medical Officer of Target RWE and is a stockholder in the company. K. Rajender Reddy has received research grants (paid to the University of Pennsylvania) for the HCV-TARGET, TARGET-HCC, and TARGET-NASH studies. Anna S. Lok has received research grants (to University of Michigan) from and served as advisor to Target RWE; and has served on the Data and Safety Monitoring Board for Novo Nordisk. The remaining authors disclose no conflicts.",

year = "2022",

month = feb,

doi = "10.1016/j.cgh.2021.03.031",

language = "English (US)",

volume = "20",

pages = "458--460.e4",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

AU - Thomson, Mary J.

AU - Serper, Marina

AU - Khungar, Vandana

AU - Weiss, L. Michael

AU - Trinh, Huy

AU - Firpi-Morell, Roberto

AU - Roden, Michael

AU - Loomba, Rohit

AU - Barritt, A. Sidney

AU - Gazis, Derek

AU - Mospan, Andrea R.

AU - Fried, Michael W.

AU - Reddy, K. Rajender

AU - Lok, Anna S.

N1 - Funding Information: Funding Marina Serper receives funding from the National Institutes of Health (award 1K23DK1158907-03 ). Mary Thomson receives funding from the American Association for the Study of Liver Diseases Advanced/Transplant Hepatology Award. TARGET-NASH is a collaboration among academic and community investigators and the pharmaceutical industry. Target RWE is the sponsor of the TARGET-NASH study. We thank the study staff, nurses, health care providers, and participants at each study center for their contributions to this work. Funding Information: Conflicts of interest These authors disclose the following: Marina Serper has received consulting fees from Gilead. Huy Trinh has served as a speaker and advisor for and owns stock in Gilead; and has received grant support from Gilead and Intercept. Michael Roden has served on the scientific advisory boards of Allergan, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Inventiva, Intercept Pharma, Novartis, Novo Nordisk, Servier Laboratories, Target Pharma Solutions, and Terra Firma; and has received investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone, and Sanofi. Derek Gazis and Andrea R. Mospan are employees of Target RWE. Michael W. Fried is is Chief Medical Officer of Target RWE and is a stockholder in the company. K. Rajender Reddy has received research grants (paid to the University of Pennsylvania) for the HCV-TARGET, TARGET-HCC, and TARGET-NASH studies. Anna S. Lok has received research grants (to University of Michigan) from and served as advisor to Target RWE; and has served on the Data and Safety Monitoring Board for Novo Nordisk. The remaining authors disclose no conflicts. Funding Information: Funding Marina Serper receives funding from the National Institutes of Health (award 1K23DK1158907-03). Mary Thomson receives funding from the American Association for the Study of Liver Diseases Advanced/Transplant Hepatology Award. TARGET-NASH is a collaboration among academic and community investigators and the pharmaceutical industry. Target RWE is the sponsor of the TARGET-NASH study. We thank the study staff, nurses, health care providers, and participants at each study center for their contributions to this work. Conflicts of interest These authors disclose the following: Marina Serper has received consulting fees from Gilead. Huy Trinh has served as a speaker and advisor for and owns stock in Gilead; and has received grant support from Gilead and Intercept. Michael Roden has served on the scientific advisory boards of Allergan, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Inventiva, Intercept Pharma, Novartis, Novo Nordisk, Servier Laboratories, Target Pharma Solutions, and Terra Firma; and has received investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone, and Sanofi. Derek Gazis and Andrea R. Mospan are employees of Target RWE. Michael W. Fried is is Chief Medical Officer of Target RWE and is a stockholder in the company. K. Rajender Reddy has received research grants (paid to the University of Pennsylvania) for the HCV-TARGET, TARGET-HCC, and TARGET-NASH studies. Anna S. Lok has received research grants (to University of Michigan) from and served as advisor to Target RWE; and has served on the Data and Safety Monitoring Board for Novo Nordisk. The remaining authors disclose no conflicts.

PY - 2022/2

Y1 - 2022/2

N2 - Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events. 1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis, 2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma. 3 , 4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. 5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.

AB - Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events. 1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis, 2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma. 3 , 4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. 5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.

UR - http://www.scopus.com/inward/record.url?scp=85105702580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105702580&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2021.03.031

DO - 10.1016/j.cgh.2021.03.031

M3 - Article

C2 - 33775894

AN - SCOPUS:85105702580

SN - 1542-3565

VL - 20

SP - 458-460.e4

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 2

ER -

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this